Please assess the completion status of the following clinical trial:

Trial Title: Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 18 years or older~* Histologically confirmed primary DLBCL of any stage~* Refractory to the last treatment regimen~* Previously treated with the following treatment regimens:~* Anthracycline-based combination chemotherapy with rituximab~* Second-line combination chemotherapy~* Autologous BMT if the subject was eligible and did not refuse the procedure~* At least one measurable lesion defined as \> 1.5 cm in the longest diameter~* No known central nervous system involvement~* ECOG performance status \< 2~* Life expectancy \> 12 weeks~* If female, non-pregnant and non-lactating~* IRB-approved consent and HIPAA Authorization~Exclusion Criteria:~* Transformed, composite or discordant lymphoma~* Therapy for lymphoma within 21 days prior to the first dose of YM155~* Within 4 weeks of the screening FDG-PET scan, receipt of the following:~* Radiation therapy~* Surgical procedures (except biopsies and central catheter / port placement)~* Active infection (bloodstream or deep tissue)~* Inadequate marrow, hepatic and/or renal function~* Serum creatinine \> 1.5 x ULN or calculated serum creatinine clearance \< 60 mL/min~* Absolute Neutrophil Count (ANC) \< 750/mm3~* Platelet \< 50,000/mm3~* Alanine Transaminase (ALT) and Aspartate Transaminase (AST) \> 2.5 x ULN; \> 5 x ULN if secondary to liver metastases~* Treated with \> 3 prior treatment regimens. The following should be considered:~* Planned maintenance therapy should be considered as part of the previous treatment regimen~* Any preparative treatment (salvage chemotherapy, high-dose chemotherapy, radiation therapy, etc.) should be included with the autologous BMT or PBSCT as one treatment~* Prior allogeneic BMT or PBSCT~* Previously treated with YM155~* Other investigational therapy or procedures within 28 days~* Known HIV, hepatitis B surface antigen, or hepatitis C antibody~* Other malignancy requiring treatment within 2 years~* Significant and/or uncontrolled cardiac, renal, hepatic, or other systemic disorders or significant psychological conditions that in the Investigator's judgment would jeopardize subject enrollment or compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).